Evidence map›Paper›PMID 38460081›Full record

ArticleInternational journal of hematology2024

Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.

Hirozumi Sano, Keitaro Fukushima, Michihiro Yano, Shinya Osone, Yoko Kato, Daiichiro Hasegawa, Takako Miyamura, Shotaro Iwamoto, Hiroyuki Takahashi, Kiminori Terui and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 12 institutions in 1 country.

Hirozumi SanoDepartment of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo, 003-0006, Japan. hirozumi.sano@gmail.com.ORCID http://orcid.org/0000-0003-4183-4602
Keitaro FukushimaDepartment of Pediatrics, Dokkyo Medical University, Mibu, Japan.
Michihiro YanoDepartment of Pediatrics, Akita University Graduate School of Medicine, Akita, Japan.
Shinya OsoneDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoko KatoDepartment of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Daiichiro HasegawaDepartment of Hematology/Oncology, Kobe Children's Hospital, Kobe, Japan.
Takako MiyamuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Shotaro IwamotoDepartment of Pediatrics, Mie University, Tsu, Japan.
Hiroyuki TakahashiDepartment of Pediatrics, Toho University, Tokyo, Japan.
Kiminori TeruiDepartment of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Akio TawaHigashiosaka Aramoto Heiwa Clinic, Higashiosaka, Japan.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Akita University · JPDokkyo Medical University · JPHeiwa (Japan) · JPHirosaki University · JPJikei University School of Medicine · JPKobe Children's Hospital · JPKyoto Prefectural University of Medicine · JPMie University · JPNational Center For Child Health and Development · JPSapporo Hokuyu Hospital · JPThe University of Osaka · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dosage of chemotherapy drugs for overweight/obese children with acute myeloid leukemia (AML) has been empirically reduced based on ideal body weight (BW) in Japan to reduce the risk of adverse events. We investigated the associations between pre-therapeutic body mass index (BMI) and clinical outcomes among children with AML. A total of 280 children were divided into two groups based on the World Health Organization Child Growth Standards: a healthy-weight group (n = 254), and an overweight/obese group (n = 26). If BW exceeded 1.2 times the standard BW of Japanese children, the dosage of chemotherapy drugs was calculated using 1.2 times the standard BW. The dosage of chemotherapy drugs was reduced during at least one chemotherapy cycle in 24 of 26 patients (92.3%) in the overweight/obese group, compared with zero patients in the healthy-weight group. Overall/event-free survival, cumulative incidence of relapse, and treatment-related mortality (TRM) did not differ between the overweight/obese and healthy weight groups. However, the frequency of bacteremia was higher in the overweight/obese group (80.8 vs. 52.4%, P = 0.006). This indicates that TRM may increase when chemotherapy drug dosage is not corrected in overweight/obese patients. Drug reduction is a potential treatment strategy.

Indexed as

Body Mass IndexLeukemia, Myeloid, AcuteOverweightAdolescentAntineoplastic AgentsChildChild, PreschoolEast Asian PeopleFemaleHumansInfantJapanMaleObesityAntineoplastic AgentsAcute myeloid leukemiaDosage reductionObesityOverweightPrognosis

Identifiers

PMID38460081
OpenAlexW4392615534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.